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Abstract 
The aim of the present study was to formulate once daily sustained release 
matrix tablets of Stavudine to increase therapeutic efficacy, reduce frequency 
of administration and improve patient compliance. The sustained release 
tablets were prepared by direct compression and formulated using different 
drug: polymer ratios, formulations such as F1to F15. Hydrophilic polymers 
like Hydroxy propyl methyl cellulose (HPMC), Carboxymethyl cellulose 
(CMC) and Starch 1500 were used. Compatibility of the drug with various 
excipients was studied. The compressed tablets were evaluated and showed 
compliance with pharmacopoeial standards. Formulation containing 
Stavudine:HPMCK15: Na-CMC (1:2:0.5) with hardness 10-11kg/cm2 
showed the desired release profile which matched the theoretical release 
profile. SEM studies of the formulations were carried out for the 
confirmation of mechanism of drug release. The in vitro drug release 
characteristics were studied in both simulated gastric and intestinal fluids for 
a period of 24 hr using USP Type 2 dissolution apparatus. Mathematical 
analysis of the release kinetics indicated a coupling of diffusion and erosion 
mechanisms. The study proves that the developed sustained release tablet is 
capable of releasing the drug in a sustained manner for 24 hr.  
 
Keywords: Sustained release; Matrix tablets; Hydroxy propyl 
methylcellulose; Stavudine 
 
Introduction  
The oral route is the most common route of drug 
administration because of its advantages in terms of 
convenient administration, thus leading to increased 
patient compliance. Extended release formulations in 
many cases provide further significant advantages, 
including improved therapeutic effect, increased patient 
compliance by reducing dosing frequency and decrease 
in incidence and /or intensity of adverse effect by a 
constant blood concentration [1]. 
 
 
Stavudine, 2’,3’-didehydro-3’-deoxythymidine (D4T) 
is a thymidine analog approved for the treatment of 
HIV infection [2]  like other member of this class of 
antiretrovirals, its purported active metabolite, D4T-5’-
triphosphate, is an inhibitor of the HIV reverse 
transcriptase and acts as a chain terminator during 
DNA synthesis [3]. 
Stavudine is currently approved by US-FDA for the 
treatment of patients who have become intolerant to or  
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failed to response to zidovudine, didanosine or 
zalcitabine therapy. The mean serum elimination half 
life reported ranges between 1 to 1.67 hr in adults. It is 
given twice daily 40 mg. Main dose related adverse 
effect is peripheral neuropathy. Converting twice daily 
regimen of stavudine into once daily improve 
adherence and, therefore, enhances the effectiveness of 
antiretroviral therapy.  
For many drugs, the optimal therapeutic response is 
observed only when adequate blood levels are achieved 
and maintained with minimal variation. Sustained 
release products have become important for the oral 
administration of many drugs because they give more 
consistent blood levels [4].  One of the most commonly 
used methods of modulating drug release is to include 
it in a matrix system. The classification of matrix 
system is based upon matrix structure, release kinetics, 
controlled released properties (diffusion, erosion, 
swelling), and the chemical nature and properties of 
employed materials [5].   
The present research endeavour was directed towards 
the development of a sustained release dosage form of 
Stavudine in the form of tablets to be taken once daily. 
Theoretical release profile was calculated based on 
pharmacokinetic parameters. Different grades of 
HPMC studied include MethocelK4M and K15M in 
different proportions to get the desired release profile 
with reduced HPMC requirement. Different filler viz. 
starch 1500 and Avicel PH101 were used.  
 
Materials and methods 
Materials 
Stavudine was obtained from M/s Cipla 
Pharmaceutical, Mumbai, India. Hydroxy propyl 
methyl cellulose (Methocel K4M Premium CR and 
K15M Premium CR) were obtained as gift samples 
from M/s Colorcon Asia Pvt Ltd, India. Pregelatinized 
Starch (Starch 1500) was obtained as a gift sample 
from M/s Dr reddys laboratory, India. Microcrystalline 
Cellulose (Avicel PH101) was obtained from M/s 
Signet chemicals, Mumbai. Aerosil 200 and stearic 
acid were obtained as a gift sample from Lupin 
Research Park, Pune, India. 
All the other reagents and solvents used were 
purchased from Merck, India and were of analytical 
grade. 
 
Methods 
Drug–excipient interaction studies 
To study the compatibility of various formulation 
excipients with Stavudine, solid admixtures were 
prepared by mixing the drug with each formulation 
excipient separately in the ratio of 1:1 and then stored 
in airtight containers at 300C±20C/65% relative 
humidity (RH) ± 5% RH. The solid admixtures were 
characterized using Fourier transform infrared 
spectroscopy (FTIR) (FTIR 8300, Shimadzu, Japan) 
and Differential scanning calorimetry (DSC) (DSC-60, 
Shimadzu). 
 
Preparation of tablets 
Tablets were made by direct compression (Formulation 
I-XV, table 1). All the powders were passed through 
ASTM (American society of testing and materials) 40 
mesh. Stavudine, half of starch 1500 and aerosil were 
blended for 5 minutes then blend was passed through 
0.4 mm sieve. HPMC and remaining half of starch 
1500 were mixed to the sieved blend and mixed for 5 
minutes and then finally stearic acid was added and 
mixed for 5 minutes. Compression was done on 
Cadmach multistation automatic compression machine 
using 10.5 mm flat face punch. Each tablet contained 
100 mg Stavudine and other pharmaceutical ingredients 
as listed in table. Prior to compression, the powder 
blends were evaluated for several tests. 
 
Evaluation of powder blend 
Angle of repose 
The angle of repose was determined by the funnel 
method. The accurately weighed powder blend was 
taken in a funnel. The height of the funnel was adjusted 
in such a way that the tip of the funnel just touched the 
apex of the heap of the powder blend. The blends were 
allowed to flow freely onto the surface. The diameter 
of the powder cone was measured and angle of repose 
was calculated using the following equation [6].  
                         tan° = h/r 
where h and r are the height and radius of the powder 
cone.  
 
Compressibility index 
To calculate the carr’s compressibility both loose bulk 
density (LBD) and tapped bulk density (TBD) was 
determined. A quantity of 2 g of powder from each 
formula, previously lightly shaken to break any 
agglomerate formed, was introduced into a 10-mL 
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measuring cylinder. After the initial volume was 
observed, the cylinder was allowed to fall under its 
own weight onto a hard surface from the height of 2.5 
cm at 2-second intervals. The tapping was continued 
until no further change in volume was noted. LBD and 
TBD was calculated and used to calculate the carr’s 
index and hausner’s ratio. 
The compressibility index of the powder blend was 
determined by carr’s compressibility index [6]. 
Carr’s index (%) = [(TBD-LBD) x 100]/TBD 
 
Table 1. Composition of various sustained release matrix formulations of stavudine 
 
Sustained release matrix formulations of stavudine Ingredients 
(%w/w) 
F-I F-
II 
F-
III 
F-
IV 
F-
V 
F-
VI 
F-
VII 
F-
VIII 
F-
IX 
F-
X 
F-
XI 
F- 
XII 
F- 
XIII 
F-
XIV 
F-
XV 
Stavudine 
 
20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 
HPMC 
K4MCR 
30 40 30 40 45 50 55 60 - - - - - - - 
HPMC 
K15MCR 
- - - - - - - - 50 55 60 50 55 60 40 
Sodium  
CMC 
- - - - - - - - - - - - - - 10 
Starch  
1500 
43 38   33 28 23 18 28 23 18 28 23 18 28 
Avicel  
PH102 
- - 43 38 - - - - - - - - - - - 
Aerosol  
200 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Stearic  
acid 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Hardness 
(kg/cm2) 
7-8 7-8 7-8 7-8 7-8 7-8 7-8 7-8 7-8 7-8 7-8 11-12 11-
12 
11-12 11-
12 
Tablet weight 
(mg) 
50
0 
500 500 500 500 500 500 500 500 500 500 500 500 500 500 
 
*HPMC is hydroxypropyl methylcellulose, Sodium CMC is sodium carboxymethylcellulose, Starch1500 is pregelatinised starch, Avicel 
PH101 is microcrystalline cellulose, and Aerosil 200 is colloidal silicon dioxide 
 
Hausner’s ratio 
This value was calculated by making use of bulk and 
tap densities of powder samples. 
                   Hausner’s ratio = TBD/LBD 
 
Drug content 
An accurately weighed amount of powder blend (100 
mg) was extracted with water and the solution was 
filtered through 0.45-µ membrane (Nunc, Delhi, India). 
The absorbance was measured at 266 nm after suitable 
dilution. 
 
Evaluation of tablets 
The thickness of the tablet was determined using a 
thickness gauge (Mitutoyo, New Delhi, India). Five 
tablets from each batch were used and average value 
were calculated.To study weight variation, 20 tablets of 
each formulation were weighed using an electronic 
balance (Denver APX-100, Arvada, Colorado), and the 
test was performed according to official method [7].To 
determine drug content, five tablets were weighed 
individually, and the drug was extracted in water. The 
drug content was determined by measuring absorbance 
at 266 nm. 
The hardness and friability of 6 tablets of each 
formulation were determined using Monsanto hardness 
tester (Cadmach, Ahmedabad, India) and the Roche 
friabilator (Campbell Electronics, Mumbai, India), 
respectively. 
 
In vitro release study 
The in vitro dissolution studies was carried out using 
USP apparatus type II (Tab-Machines, Mumbai, India) 
at 75 rpm. For the first 2 hr the dissolution medium was 
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0.1 N hydrochloric acid and phosphate buffer pH 7.4 
from 3-24 hr (900 mL), maintained at 370C±0.50C. At 
each time point 5 mL of sample was withdrawn and it 
was replaced with 5 mL of fresh medium. The drug 
release at different time interval was measured by UV-
visible spectrophotometer (UV-1601PC, Shimadzu, 
Japan). It was made clear that none of the ingredient 
used in the matrix formulations interfered with the 
assay. The release studies were conducted in triplicate 
(6 tablets in each set), and the mean values were 
plotted versus time. 
 
Table 2.  Micromeritic properties of formulation 
blend. 
 
Compostion Angle of 
repose 
 (°) 
Carr’s index 
 (%) 
Hausner 
ratio 
Drug 
content 
Stavudine 40.12±0.138 18.55±0.058 1.700±0.012 99.85±0.185 
F-I 24.24±0.126 13.21±0.046 1.437±0.012 99.25±0.101 
F-II 24.18±0.116 12.64±0.076 1.263±0.025 98.52±0.124 
F-III 23.98±0.128 12.10±0.056 1.227±0.058 99.10±0.298 
F-IV 23.68±0.132 11.78±0.048 1.197±0.062 98.52±0.187 
F-V 23.72±0.116 11.12±0.072 1.182±0.045 98.65±0.210 
F-VI 23.45±0.127 10.88±0.056 1.167±0.035 97.85±0.234 
F-VII 23.26±0.119 10.48±0.062 1.128±0.034 98.74±0.318 
F-VIII 22.82±0.124 10.86±0.068 1.152±0.065 98.83±0.242 
F-IX 23.68±0.118 11.24±0.058 1.144±0.023 98.09±0.364 
F-X 23.46±0.124 11.36±0.066 1.143±0.032 98.86±0.235 
F-XI 22.48±0.114 12.11±0.064 1.137±0.012 98.23±0.259 
F-XII 23.68±0.118 11.88±0.052 1.133±0.020 97.76±0.129 
F-XIII 23.46±0.124 11.64±0.054 1.152±0.032 98.92±0.103 
F-IV 22.48±0.114 11.24±0.048 1.148±0.018 97.85±0.205 
F-XV 23.38±0.126 12.12±0.060 1.293±0.052 98.78±0.264 
*All values are expressed as Mean±SD, n=3. 
 
Calculation of theoretical release profile 
Dose of Stavudine were calculated on the basis of 
pharmacokinetic parameters [8] as follows: 
 
       Dose of immediate release part= Css.Vd/F 
 
where Css = steady state plasma concentration 
(228ng/mL), Vd = volume of distribution (35 Litre, for 
70 kg human), F=  bioavilability (83%). 
 
Dose of immediate release part= 228x35x100/83 = 
9.614mg. 
To maintain the drug concentration in the blood, rate of 
elimination of drug should be equal to rate of drug 
absorption hence rate of drug release from the dosage 
form. 
Rate of elimination = Ke.Cd.Vd= 0.4150x0.228x35 
=3.3117 mg/h. 
where; Ke = elimination rate constant (0.693/t1/2), Cd = 
desired drug level in the body, Vd = volume of 
distribution. Bioavailability of  Stavudine is 83% so 
amount required to release from dosage form to 
maintain the steady state of drug in plasma is 
3.3117x100/83 = 3.99 mg. Hence, the formulation 
should release 9.614 mg in 1 hr and 3.99 mg per hr up 
to 24 hr. 
 
Results and discussion 
Drug- excipient interaction studies 
The supplied drug passed the various tests of 
identification and analysis as per the certificate of 
analysis given by the supplier. FTIR spectra of pure 
Stavudine and solid admixtures of Stavudine with 
various excipients used in the preparation of matrix 
tablet formulations are shown in Figure 1.  
 
 
 
Figure 1. IR spectra of Stavudine and Stavudine-
excipient mixtures.  Stavudine (A), stavudine + 
HPMC K4M (B), stavudine + HPMC K15 M (C), 
stavudine + starch 1500 (D), stavudine + avicel 
PH101 (E), stavudine + sodium CMC (F). 
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Table 3. Physical characteristics of designed matrix tablets of stavudine. 
 
Formulations Thickness* 
(mm) 
Hardness† 
(kg/cm2) 
Friability†* 
(%) 
    Weight 
variation‡ (%) 
 
Drug 
content* (%)       
F-1 4.86±0.023 7.2±0.080 0.65±0.062 2.10±0.056 98.85±0.185 
F-II 4.85±0.045 7.1±0.088 0.64±0.092 3.12±0.059 98.25±0.101 
F-III 4.80±0.036 7.2±0.095 0.65±0.035 3.02±0.135 98.52±0.124 
F-IV 4.90±0.024 7.4±0.082 0.62±0.039 3.12±0.162 99.10±0.298 
F-V 4.85±0.021 7.6±0.120 0.68±0.051 2.45±0.052 98.52±0.187 
F-VI 4.90±0.080 7.3±0.103 0.61±0.039 3.25±0.067 98.65±0.210 
F-VII 4.85±0.075 7.6±0.053 0.60±0.012 3.46±0.210 98.25±0.234 
F-VIII 4.88±0.086 6.9±0.075 0.65±0.091 3.71±0.920 98.24±0.318 
F-IX 4.95±0.069 7.2±0.085 0.65±0.078 2.98±0.350 101.2±0.242 
F-X 4.75±0.063 7.0±0.064 0.50±0.089 3.12±0.602 98.09±0.364 
F-XI 4.85±0.058 6.9±0.124 0.55±0.060 2.95±0.813 98.86±0.235 
F-XII 4.55±0.049 10.2±0.161 0.53±0.090 2.65±0.510 98.23±0.259 
F-XIII 4.60±0.064 10.4±0.091 0.58±0.039 3.62±0.235 98.76±0.129 
F-XIV 4.50±0.062 10.4±0.082 0.54±0.023 3.05±0.263 98.92±0.103 
F-XV 4.50±0.081 10.3±0.073 0.44±0.071 2.91±0.512 98.85±0.205 
 
All values are expressed as Mean± SD; * n=5; †n=10; †*n=20; ‡n=20. 
The characteristic peak of the carbonyl group (present 
in the cytidine nucleus) at 1691 cm−1; a band of peaks 
at 3425 cm−1 owing to amino groups; and peaks at 
1286 and 1161 cm−1 owing to asymmetrical and 
symmetrical stretching of the C-O-C system (present in 
the oxathiolane ring), respectively, in all the spectrum, 
indicate the stable nature of Stavudine in the solid 
admixtures of the drug with various excipients. This 
finding was further supported by DSC studies. 
 
Evaluation of powder blend 
The results of micromeritic properties of the drug and 
the composition of formulations are presented in Table 
2. The method employed for compression in this study 
was direct compression for which the powder blend 
should possess good flow and compacting properties. 
Plain Stavudine exhibited angle of repose value of 
40.12±0.1380 indicating extremely poor flow property. 
The DSC thermogram of pure Stavudine showed a 
sharp melting endotherm at 1680C with a normalized 
energy of 103.9 J/g, as shown in Figure 2. The 
thermograms of solid admixtures of Stavudine with 
various excipients also showed a similar peak at 1680C 
with almost the same normalized energy, indicating 
that Stavudine is unaffected in the presence of various 
excipients used in the preparation of matrix tablet 
formulations.  
 
 
Figure 2. Differential scanning calorimetry (DSC) 
thermograms of pure Stavudine (a) and its solid 
admixture with hydroxypropyl methylcellulose 
(HPMC) 4000 cps (b), HPMC 15 000 cps (c), starch 
1500 (d), sodium-CMC (e), aerosil (f), and stearic 
acid (g),  at a heating rate of 100C/min using 
nitrogen environment. 
 
Kumar et al. International Journal of Drug Delivery 2 (2010) 125-134 
 
 130
It was further supported by higher Carr’s index value 
of 18.55±0.058% and Hausner’s ratio of 1.700±0.012. 
Prepared powder blend have shown a significant 
increase in the flow properties as indicated by 
reduction in the values of angle of repose8 (<30), Carr’s 
index9 (<15 %) and Hausner’s ratio (<1.5). The final 
micromeritic values of powder blend make it suitable 
for direct compression. 
 
Evaluation of tablets 
The physical appearance, tablet hardness, friability, 
weight variation, and drug content uniformity of all 
tablet formulations were found to be satisfactory and 
reproducible as observed from the data in table 3. 
Tablet hardness was found to be good (6.9±0.124 to 
10.4 ± 0.091 kg/cm2) depending on the compression 
force applied. In the present study, the percentage 
friability for all the formulations was found below 1% 
indicating that friability (%) is within the acceptable 
limits[9]. In a weight variation test, the pharmacopoeial 
limit for the percentage deviation for tablets of more 
than 250 mg is ±5%. The average percentage deviation 
of all tablet formulations was found to be within above 
limit, and hence all formulations passed the test for 
uniformity of weight as per official requirement. Good 
uniformity in drug content was found among different 
batches of the tablets, and the percentage of drug 
content was more than 98 %, which indicates that by 
direct compression we can get a good quality of 
stavudine matrix tablets. 
 
In vitro release study 
The in vitro drug release characteristics were studied in 
simulated gastric and intestinal fluids for a period of 24 
hr using USP XXIII dissolution apparatus 2. The 
theoretical release profile calculation is important to 
evaluate the formulation with respect to release rates 
and to ascertain whether it releases the drug in a 
predetermined manner [10]. According to the 
theoretical release pattern, a once-daily Stavudine 
sustained-release formulation should release 9.614 mg 
in 1 hr and 3.99 mg per hr up to 24 hr. The results of 
dissolution studies indicated that F-I, F-II, F-III, F-IV 
and F-IV released 18.62,  17.64,  23.15, 23.07 and  
17.13% of Stavudine at the end of 1 hr; and 76.83, 
72.84, 79.38, 76.86 and 70.16 at the end of 12 hr 
respectively (Figure 3).  
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Figure 3. The In vitro release profiles of Stavudine 
from F-I, FII, F-III, F-IV and F-V formulations. 
n=3.Theoretical ( ), F-I ( ), F-II ( ), F-III 
( ),F-IV ( ) and F-IV(V ). 
 
Among these formulations, F-I and F-II contain 
pregelatinized starch as filler and F-III and F-IV 
contain microcrystalline cellulose as filler. Drug: 
polymer ratio in F-I and F-III (1:1.5) and F-II and F-IV 
(1:2).  
 
Table  4. Kinetic values obtained from different 
plots of formulations, F-I to F-Xv. 
 
First 
Order 
Plots * 
Higuchi’s 
Plot † 
Korsmeyer et al’s 
Plot‡ 
Formulations 
Regression 
coefficient 
I 
Regression 
coefficient 
I 
Slope 
(n) 
Regression 
coefficient 
I 
F-I 0.9858 0.9945 0.5535 0.9837 
F-II 0.9859 0.9944 0.5581 0.9865 
F-III 0.9851 0.9963 0.4881 0.9944 
F-IV 0.9787 0.9942 0.4813 0.9925 
F-V 0.9872 0.9963 0.5671 0.9943 
F-VI 0.9772 0.9955 0.5536 0.9967 
F-VII 0.9796 0.9949 0.5566 0.9963 
F-VIII 0.9753 0.9943 0.5484 0.9971 
F-IX 0.9921 0.9804 0.6256 0.9939 
F-X 0.8955 0.9785 0.6276 0.9924 
F-XI 0.9085 0.9787 0.6273 0.9927 
F-XII 0.9228 0.9741 0.6113 0.9934 
F-XIII 0.9541 0.9810 0.6067 0.9952 
F-XIV 0.9639 0.9878 0.5955 0.9954 
F-XV 0.9019 0.9728 0.6572 0.9913 
 
*First order equation, Log C = log C – Kt/2.303. † Higuchi’s equation, Q = 
Kt1/2. ‡ Korsmeyer et al’s equation, Mt/Ma = Ktn 
 
The release results showed that pregelatinized starch is 
better release retarding than microcrystalline cellulose.  
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Release of Stavudine at the end of 1 hr and at the end 
of 12 hr in all the five formulations was more than the 
theoretical. Further optimization of release was done by 
taking higher concentration of HPMC and 
pregelatinized starch was taken as filler for further 
formulation development. As the release rate of first 
five formulations in first 12 hr was high, proportion of 
HPMC was increased to decrease the release rate [11] 
have reported that by increasing the concentration of 
HPMC the release rate of drug decreases. This was 
because an increase in polymer concentration caused 
an increase in the viscosity of the gel (by making it 
more resistant to drug diffusion and erosion) as well as 
the formation of a gel layer with a longer diffusional 
path.Formulations F-VI, F-VII and F-VIII contain drug 
: polymer ratio 1:2.5, 1:2.75 and 1:3 respectively while 
the tablet was kept constant at 500 mg. The results of 
dissolution studies showed that F-VI, F-VII and F-VIII 
released 16.12, 15.88 and 16.28 % of Stavudine at the 
end of 1 hr and 64.12, 63.02 and 62.06 % of Stavudine 
at the end of 12 hr; and 98.88, 98.1 and 97.68 % of 
Stavudine at the end of 24 hr (Figure 4). When the 
profile was compared with theoretical release profile 
the release was found to be more at each time point. 
Hence, initial burst release and high deviation in the 
release profile from the theoretical release pattern 
demonstrated the need for further development to find 
a suitable formulation to mimic the theoretical pattern. 
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Figure 4. The in vitro release profiles of Stavudine 
from F-VI, F-VII, and F-VIII formulations. n=3. 
Theoretical ( ), F-VI ( ), F-VII( ),F-VII 
( ). 
 
In the further formulation development process, HPMC 
K15M CR instead of K4M CR grade in the ratio 2.5, 
2.75 and 3.0 with drug was taken for formulations F-
IX, F-X and F-XI respectively. The higher viscosity 
grade was chosen to decrease the release rate because 
the diffusion co-efficient is inversely proportional to 
viscosity. The tablets were compressed at hardness of 7 
kg/cm2 (with similar hardness as previous eight 
formulations). The result of dissolution studies showed 
that F-IX, F-X and F-XI released 14.76, 14.09 and 
14.02 % of Stavudine at the end of 1 hr and 63.24, 
61.85 and 60.49 % of Stavudine at the end of 12 hr; 
and 98.22, 98.24 and 97.49 % of stavudine at the end 
of 24 hr (Figure 5).  
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Figure 5. The in vitro release profiles of Stavudine 
from F-IX, F-X, and F-XI formulations. n=3. 
Theoretical ( ), F-IX ( ), F-X ( ) and F-XI 
( ). 
 
In these formulations the release rate decreased but the 
burst effect continued and was more than the desired 
theoretical release. Hence the formulation had to be 
developed further to minimize the burst effect. To 
control the burst effect and release rate, further 
formulations (F-XII, F-XIII and F-XIV) were prepared 
with same composition of polymer as (F-IX, F-X and 
F-XI) but the tablet hardness was increased from 7-8 
kg/cm2 to 10-11 kg/cm2. The results of dissolution 
studies showed that F-XII, F-XIII and F-XIV released 
13.68, 13.62 and 13.64 % of Stavudine at the end of 1 
hr; 56.16, 56.08 and 55.68 at the end of 12 hr; 94.89, 
91.84 and 89.74 at the end of 24 hr (Figure 6). The 
results indicated that by increasing the hardness the 
burst effect decreases but not significantly as supported 
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by previous studies [13,14].  The release rate decreased 
which resulted into less release at the end of 24 hr. F-
XII released 94.89 % of Stavudine at the end of 24 hr 
and its release profile was similar to the theoretical 
profile but it showed a burst effect in 1st hr. Hence 
formulation F-XII was chosen for further development. 
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Figure 6. The in vitro release profiles of Stavudine 
from F-XII, F-XIII, and F-XIV formulations. n=3. 
Theoretical ( ), F-XII ( ), F-XIII ( ) and F-
XIV( ). 
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Figure 7. The in vitro release profiles of Stavudine 
from F-XV formulation. Theoretical ( ), F-XV 
( ). n=3.  
 
As clearly indicated in Figure 1, the formulation F-I to 
F-V did not follow a zero order release pattern. The 
release rate kinetics data for all the other equation can 
be seen in table 4. When the data was plotted according 
to the first-order equation, the formulation showed a 
fair linearity. Release of the drug from a matrix tablet 
containing hydrophilic polymers generally involves 
factors of diffusion. Diffusion is related to transport of 
drug from the dosage matrix into the in vitro study 
fluid depending on the concentration. As gradient 
varies, the drug is released, and the distance for 
diffusion increases. This could explain why the drug 
diffuses at a comparatively slower rate as the distance 
for diffusion increases, which is referred as square-root 
kinetics or Higuchi’s kinetics [15]. In our experiments, 
the in vitro release profiles of drug from all the 
formulations could be best expressed by Higuchi’s 
equation, as the plots showed high linearity (R2: 0.9728 
to 0.9963). To confirm the diffusion mechanism, the 
data were fit into Korsmeyer et al’s [16] equation. The 
formulations F-I to F-XV showed good linearity (R2: 
0.9837 to 0.9971), with slope (n) values ranging from 
0.4813 to 0.6572, indicating that diffusion is the 
dominant mechanism of drug release with these 
formulations. 
 
The burst effect of formulation F-XII was reduced by 
adding a polymer that hydrated quickly. As reported 
addition of Na-CMC with HPMC  minimizes the initial 
release of soluble drug during initial phase of  release 
profile [11,12]. So in F-XII 10%wt/wt of Na-CMC was 
added and F-XV was compressed with 
Drug:HPMC:Na-CMC (1:2:0.5). The tablets were 
compressed with hardness value of 10-11 Kg/cm2. The 
result of dissolution studies showed that the burst effect 
was decreased (10.98%) and the release profile was 
similar to the desired theoretical pattern (Figure 7). To 
know the mechanism of drug release from these 
formulations, the data was treated according to first-
order (log cumulative percentage of drug remaining 
versus time), Higuchi’s (cumulative percentage of drug 
released vs square root of time), and Korsmeyer et al’s 
[15, 16] log cumulative percentage of drug released 
versus log time) equations along with zero order 
(cumulative amount of drug released versus time) 
pattern. 
 
  
 
Figure 8. SEM photomicrographs of optimized matrix tablet (Formulation XV) showing surface morphology 
after 0 hours (A, 35X), and 24 hours (B, 100X) of dissolution study. (Arrow indicates the formation of pores 
on matrix surface). 
 
When plotted according to Korsmeyer et al’s equation, 
formulation F-XV also showed high linearity (R2: 
0.9913), with a comparatively high slope (n) value of 
0.6572. This n value, however, appears to indicate a 
coupling of diffusion and erosion mechanisms so-
called anomalous diffusion. The relative complexity of 
this formulation and its components may indicate that 
the drug release is controlled by more than one process. 
Similar results were observed by Fassihi and Ritschel 
with matrix tablets of theophylline containing EC; they 
considered the n value of about 0.7 to be indicative of 
an anomalous release mechanism [17]. Hence, 
diffusion coupled with erosion may be the mechanism 
for the drug release from F-XV. Further the SEM of 
tablet indicates the formation of pores and sign of 
erosion which support the finding of release 
mechanism. 
 
Conclusions 
Sustained release matrix tablets of Stavudine were 
prepared by direct compression. Drug content was 
found to be uniform with all the formulations. 
Formulations containing HPMC, Starch 1500 did not 
show satisfactory release due to burst effect. The 
formulation containing Stavudine:HPMC 
(K15):NaCMC (1:2:0.5) with hardness 10-11kg/cm2 
showed the desired release profile with reduced burst 
effect. SEM studies of the formulation revealed that the 
formation of both pores and gelling structure on tablet 
surface. Drug release was found to follow anomalous 
diffusion. In conclusion the present study demonstrated 
the successful preparation of stable once daily extended 
release matrix tablet of Stavudine. 
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